Asset Details
Do you wish to reserve the book?
GSTM1 and GSTP1 Polymorphisms Affect Outcome in Colorectal Adenocarcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
GSTM1 and GSTP1 Polymorphisms Affect Outcome in Colorectal Adenocarcinoma
Do you wish to request the book?
GSTM1 and GSTP1 Polymorphisms Affect Outcome in Colorectal Adenocarcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
GSTM1 and GSTP1 Polymorphisms Affect Outcome in Colorectal Adenocarcinoma
2024
Overview
Background and Objectives: Despite improvements in screening programs, a large number of patients with colorectal cancer (CRC) are diagnosed in an advanced disease stage. Previous investigations imply that glutathione transferases (GSTs) might be associated with the development and progression of CRC. Moreover, the detoxification mechanism of oxaliplatin, which represents the first line of treatment for advanced CRC, is mediated via certain GSTs. The aim of this study was to evaluate the significance of certain GST genetic variants on CRC prognosis and the efficacy of oxaliplatin-based treatment. Materials and Methods: This prospective study included 523 patients diagnosed with CRC in the period between 2014 and 2016, at the Digestive Surgery Clinic, University Clinical Center of Serbia, Belgrade. Patients were followed for a median of 43.47 ± 17.01 months (minimum 1–63 months). Additionally, 109 patients with advanced disease, after surgical treatment, received FOLFOX6 treatment as a first-line therapy between 2014 and 2020. The Kaplan–Meier method was used to analyze cumulative survival, and the Cox proportional hazard regression model was used to study the effects of different GST genotypes on overall survival. Results: Individuals with the GSTM1-null genotype and the GSTP1 IleVal+ValVal (variant) genotype had significantly shorter survival when compared to referent genotypes (GSTM1-active and GSTP1 IleIle) (log-rank: p = 0.001). Moreover, individuals with the GSTM1-null genotype who received 5-FU-based treatment had statistically significantly shorter survival when compared to individuals with the GSTM1-active genotype (log-rank: p = 0.05). Conclusions: Both GSTM1-null and GSTP1 IleVal+ValVal (variant) genotypes are associated with significantly shorter survival in CRC patients. What is more, the GSTM1-null genotype is associated with shorter survival in patients receiving FOLOFOX6 treatment.
Publisher
MDPI AG
Subject
/ Adenocarcinoma - drug therapy
/ Adult
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Colorectal Neoplasms - drug therapy
/ Colorectal Neoplasms - genetics
/ Colorectal Neoplasms - mortality
/ Enzymes
/ Female
/ Fluorouracil - therapeutic use
/ Genotype
/ Glutathione S-Transferase pi - genetics
/ Glutathione Transferase - genetics
/ Humans
/ Kinases
/ Leucovorin - therapeutic use
/ Male
/ Mutation
/ Organoplatinum Compounds - therapeutic use
/ Oxaliplatin - therapeutic use
/ Patients
/ Proteins
/ Serbia
/ Smoking
/ survival
